LEVOFENFLURAMINE (+)-CAMPHORATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C12H16F3N.C10H16O4
Molecular Weight	431.489
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of LEVOFENFLURAMINE (+)-CAMPHORATE

Structure Search

SMILES

CC1(C)[C@H](CC[C@@]1(C)C(O)=O)C(O)=O.CCN[C@H](C)CC2=CC(=CC=C2)C(F)(F)F

InChI

InChIKey=GBMYZGXLAHAFPC-HJYVOTIRSA-N

InChI=1S/C12H16F3N.C10H16O4/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15;1-9(2)6(7(11)12)4-5-10(9,3)8(13)14/h4-6,8-9,16H,3,7H2,1-2H3;6H,4-5H2,1-3H3,(H,11,12)(H,13,14)/t9-;6-,10+/m11/s1

HIDE SMILES / InChI

Molecular Formula	C10H16O4
Molecular Weight	200.2316
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C12H16F3N
Molecular Weight	231.2573
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9824670 | https://www.ncbi.nlm.nih.gov/pubmed/2886127 | https://www.ncbi.nlm.nih.gov/pubmed/11224055

LEVOFENFLURAMINE is a levorotatory enantiomer of fenfluramine, a substituted amphetamine which was formerly used to treat obesity. LEVOFENFLURAMINE has dopamine-antagonistic properties and, at high doses, increases dopamine concentrations in rat striatal dialysates. It is essentially inactive to reduce food intake in human subjects.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine receptor 60 Target ID: CHEMBL2096905 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9824670 \| https://www.ncbi.nlm.nih.gov/pubmed/2886127 \| https://www.ncbi.nlm.nih.gov/pubmed/3485052	Antagonist 2849
serotonin secretion 8 Target ID: GO:0001820 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2598057 \| https://www.ncbi.nlm.nih.gov/pubmed/3485052	Activator 1447

PubMed

Title	Date	PubMed
Off-label promotion, on-target sales.	2008-10-28	18959472
Medicine as a corporate enterprise, patient welfare centered profession, or patient welfare centered professional enterprise?	2005-11	22679354
(+)-Fenfluramine and its major metabolite, (+)-norfenfluramine, are potent substrates for norepinephrine transporters.	2003-06	12649307
Effects of fenfluramine and phentermine (fen-phen) on dopamine and serotonin release in rat striatum: in vivo microdialysis study in conscious animals.	1998-11-30	9824670
The effects of D- and L-fenfluramine (and their interactions with D-amphetamine) on psychomotor function and mood.	1996-06	8803646
Differential effects of d-fenfluramine, l-fenfluramine and d-amphetamine on the microstructure of human eating behaviour.	1991-04	11224055
Neuroleptic-like effects of the l-isomer of fenfluramine on striatal dopamine release in freely moving rats.	1987-07-15	2886127

Substance Class	Chemical Created by `admin` on `Tue Apr 01 19:11:42 GMT 2025` Edited by `admin` on `Tue Apr 01 19:11:42 GMT 2025`
Record UNII	P91T3X0361
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CAMPHORIC ACID, COMPOUND WITH (R)-N-ETHYL-ALPHA-METHYL-3-(TRIFLUOROMETHYL)PHENETHYLAMINE (1:1)

Preferred Name

English

LEVOFENFLURAMINE (+)-CAMPHORATE

Common Name

English

1,3-CYCLOPENTANEDICARBOXYLIC ACID, 1,2,2-TRIMETHYL-, (1R-CIS)-, COMPD. WITH (R)-N-ETHYL-.ALPHA.-METHYL-3-(TRIFLUOROMETHYL)BENZENEETHANAMINE (1:1)

Systematic Name

English

BENZENEETHANAMINE, N-ETHYL-.ALPHA.-METHYL-3-(TRIFLUOROMETHYL)-, (R)-, (1R-CIS)-1,2,2-TRIMETHYL-1,3-CYCLOPENTANEDICARBOXYLATE (1:1)

Systematic Name

English

Code System Code Type Description

EPA CompTox

DTXSID30242739